IBM CEO Arvind Krishna forecasts that quantum computing will begin generating revenue by 2028, as investments and competition grow in the sector.
IBM's CEO Arvind Krishna predicts that the company will start generating revenue from quantum computing by 2028 or 2029, as competition intensifies in the burgeoning sector.
Investment and Innovation in Quantum Technology
During a recent interview on CNBC's Mad Money, Krishna expressed strong confidence in the commercial potential of quantum computing, stating that it is moving beyond research and into practical applications that will benefit IBM’s financial performance.
He highlighted that by the end of the 2030s, the sector could hold a trillion-dollar market value. This optimism is bolstered by significant investments, including a $1 billion commitment from the U.S. Department of Commerce paired with IBM's own investment to establish a dedicated quantum chip foundry.
IBM is not alone in this race; competitors like Alphabet, IonQ, and Rigetti Computing are also striving to develop quantum computers capable of solving complex problems that traditional computers struggle with. Krishna noted that quantum technology offers the ability to conduct calculations at speeds and efficiencies far surpassing current capabilities.
As the industry evolves, there is growing interest from the cryptocurrency sector, particularly among Bitcoin miners. Companies such as MARA Holdings and Riot Platforms are diversifying their operations to include high-performance computing, recognizing the potential implications of quantum advancements on security and infrastructure.
While concerns exist regarding the future of encryption in the crypto space, experts believe that the threat from quantum computing is still years away, allowing time for the development of quantum-resistant encryption methods.
Overall, the advancements in quantum computing are not only attracting interest but also prompting a reevaluation of existing technologies and their applications across various fields, including material science and drug development.
